Friday , 22 November 2024
Home Health Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Health

Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M

Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion.

The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin

Kura Oncology already had a broad development plan for ziftomenib in leukemias,...

How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?

Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...

Everything You Need to Know About Hip Replacement Surgery in India

Hip replacement surgery is one of the most common and successful medical...

Speculation on RFK Jr. as HHS Secretary

From Tyler Cowen at Marginal Revolution: One of the problems with an...